NYSE:CTLT - Catalent Stock Price, News, & Analysis

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) posted its quarterly earnings data on Tuesday, August, 28th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.61 by $0.06. The business had revenue of $685.30 million for the quarter, compared to analyst estimates of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. Catalent's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.65 earnings per share. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Catalent.

Catalent updated its FY18 earnings guidance on Monday, July, 23rd. The company provided EPS guidance of $1.71-1.75 for the period, compared to the Thomson Reuters consensus estimate of $1.68. The company issued revenue guidance of $2.461-2.464 billion, compared to the consensus revenue estimate of $2.47 billion.Catalent also updated its Q4 guidance to $0.62-0.64 EPS.

12 brokers have issued 12-month price objectives for Catalent's shares. Their forecasts range from $48.00 to $55.00. On average, they expect Catalent's share price to reach $49.50 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for Catalent.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC) and Valeant Pharmaceuticals (VRX).

Media coverage about CTLT stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a news impact score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Catalent.

Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.85%), Janus Henderson Group PLC (4.80%), FMR LLC (2.61%), American Century Companies Inc. (2.29%), Schroder Investment Management Group (2.22%) and Earnest Partners LLC (1.91%). Company insiders that own Catalent stock include Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schroder Investment Management Group, Northern Trust Corp, Wells Fargo & Company MN, Voya Investment Management LLC, OppenheimerFunds Inc., Schroder Investment Management Group and Schwab Charles Investment Management Inc.. Company insiders that have sold Catalent company stock in the last year include John R Chiminski, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC, Macquarie Group Ltd., Paloma Partners Management Co, Janus Henderson Group PLC, Jane Street Group LLC, LMR Partners LLP and American Century Companies Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $42.65.

Catalent has a market capitalization of $6.19 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]